Cost-effectiveness analysis of a prognostic risk assessment for early-stage 1-3b diabetic kidney disease patients in the United States.

Jacie T Cooper¹, John E Schneider², Thomas Mclain³, Steven Coca^4,5, Michael J Donovan^3,5

¹Avalon Health Economics, Miami, FL, USA. jacie.cooper@avalonecon.com.

²Avalon Health Economics, Miami, FL, USA.

³Renalytix, New York, NY, USA.

⁴Renalytix, Mount Sinai, New York, USA.

⁵Ichan School of Medicine at Mt. Sinai, New York, NY, USA.

PubMed DOI

Abstract

BACKGROUND: Diabetic kidney disease (DKD) accounts for 44% of new chronic kidney disease cases and is associated with significant morbidity and mortality. Although sodium-glucose co-transporter-2 inhibitors (SGLT2is) can reduce cardiorenal outcomes, current DKD staging relying on eGFR and albuminuria (KDIGO risk categories) leaves SGLT2is underutilized in clinical practice. A new biomarker-enriche…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.